SAN
DIEGO, June 2, 2022 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
the appointment of Amin Kamel,
Ph.D., as Vice President, DMPK. In his role, Dr. Kamel will support
clinical development, in particular advancement of the Company's
lead candidate, RGLS8429, which is being developed for patients
with autosomal dominant polycystic kidney disease (ADPKD).
In connection with his hiring, Dr. Kamel received an option to
purchase 200,000 shares of Regulus' common stock, with an exercise
price of $0.29 per share, which is
equal to the fair market value on the grant date. The option has a
10-year term and vests over a period of four years, with 25%
vesting on June 1, 2023, which is one
year following the date of grant and the remaining 75% vesting
ratably over the succeeding thirty-six months, subject to Dr.
Kamel's continuous service through each vesting date, and subject
to the terms and conditions of Regulus' Inducement Plan and stock
option grant notice and agreement thereunder. The option was
granted under Nasdaq Listing Rule 5635(c)(4) as an inducement
material to Dr. Kamel entering into employment with the
Company.
"We are excited to welcome Dr. Kamel to the Regulus team," said
Denis Drygin, Chief Scientific
Officer of Regulus. "We look forward to utilizing his expertise
working with small molecule, biologic, nanoparticle and RNAi based
therapies across multiple disease areas. His background in
designing and executing in vivo and in vitro drug metabolic studies
will be an asset as we prepare for initiation of our Phase 1
clinical study."
"I'm excited by the work Regulus is doing with RNA
therapeutics," said Dr. Kamel. "The company has a robust clinical
program on the horizon, including the initiation of a Phase 1
single-ascending dose (SAD) study in healthy volunteers to assess
safety, tolerability and pharmacokinetics of RGLS8429. I'm looking
forward to contributing my experience as we work to improve
outcomes for patients with ADPKD."
Prior to joining Regulus, Dr. Kamel was the Scientific Director
of Takeda, Drug Metabolism and Pharmacokinetics, where he was
responsible for project management, operations, and served as a
scientific advisor. Prior to Takeda, Dr. Kamal was the Principal
Investigator at Biogen, where he led project management and
provided scientific expertise and support for small molecule drug
discovery and early development. Previously, he worked as a
Research Investigator for Novartis Institutes for BioMedical
Research, and, prior to that, worked for a number of years as a
research scientist at Pfizer Global Research and Development. Dr.
Kamel holds a Ph.D. in Chemistry from the University of Rhode Island with collaboration with
University of Delaware.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate
headquarters in San Diego,
CA.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-appoints-amin-kamel-phd-as-vice-president-dmpk-301559891.html
SOURCE Regulus Therapeutics Inc.